2019
Pharmacotherapies for PTSD and Substance Use Disorders
Kachadourian L, Jensen K, Sofuoglu M, Petrakis I. Pharmacotherapies for PTSD and Substance Use Disorders. 2019, 239-259. DOI: 10.4324/9781315442648-13.ChaptersOpioid use disorderAlcohol use disorderPosttraumatic stress disorderUse disordersPTSD/SUDPharmacological treatmentComorbid posttraumatic stress disorderUse of pharmacotherapySubstance use disordersEffectiveness of foodIntramuscular naltrexoneLabel medicationsEpidemiological studiesMedication developmentDrug AdministrationPharmacotherapyStress disorderAvailable evidenceDisordersNew targetsNaltrexoneTreatmentBiological mechanismsSpecific substancesSUD
2018
Pharmacological and Psychological Treatments for Comorbid Alcohol Use Disorder and Depressive Disorder: a Review
Yoon G, Petrakis I. Pharmacological and Psychological Treatments for Comorbid Alcohol Use Disorder and Depressive Disorder: a Review. Current Addiction Reports 2018, 5: 312-322. DOI: 10.1007/s40429-018-0213-z.Peer-Reviewed Original ResearchComorbid alcohol use disorderAlcohol use disorderPsychological interventionsCognitive-behavioral treatmentUse disordersPsychological treatmentDepressive disorderMotivational interviewingComorbid disordersMixed resultsDisordersInterventionRecent FindingsWePharmacological interventionsCurrent reviewEffective treatmentFurther researchReviewThe goalInterviewingAntidepressantsPatientsTreatmentDepressionTrialsEfficacy
2013
Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence
Ralevski E, Jane J, O’Brien E, Edens E, Arnaout B, Kerfoot K, Keegan K, Weiner J, Russo M, Petrakis I. Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence. Journal Of Dual Diagnosis 2013, 9: 301-310. DOI: 10.1080/15504263.2013.835163.Peer-Reviewed Original ResearchDepressive symptomsAlcohol dependenceDual diagnosisRates of smokingMain outcome variablesSymptoms of depressionTreatment of peopleTreatment trialsComorbid depressionMecamylamineSide effectsNonsmokersSmokingSymptomsOutcome variablesBest treatmentDrinking outcomesDepressionPlaceboSmokersFurther studiesSignificant differencesDiagnosisParticipantsTreatmentChapter 38 Disulfiram for Alcohol and Other Drug Use
Kerfoot K, Petrakis I. Chapter 38 Disulfiram for Alcohol and Other Drug Use. 2013, 367-374. DOI: 10.1016/b978-0-12-398338-1.00038-5.Peer-Reviewed Original ResearchUse disordersEfficacy of disulfiramAlcohol use disorderClinical research studiesCocaine use disorderDisulfiram useFirst medicationCardiorespiratory collapseIngested alcoholRare caseDrug AdministrationUS FoodDrug useAlcohol dependenceAddiction treatmentDisulfiramTreatmentNormal metabolismDisordersPositive outcomesPotential usefulnessNauseaMedicationsHeadacheAdministration
1998
Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts
Petrakis I, Carroll K, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug And Alcohol Dependence 1998, 50: 221-226. PMID: 9649975, DOI: 10.1016/s0376-8716(98)00032-5.Peer-Reviewed Original ResearchConceptsCocaine useOpioid addictsMedication effectsDepressive symptomsSignificant decreaseEffectiveness of fluoxetineSelf-reported cocaine useDrug use outcomesSubsample of subjectsFluoxetine treatmentUrine toxicologySelf-reported useDepressive disorderSevere depressionHeroin useFluoxetineEffective agentUse outcomesDepressionPlaceboSignificant differencesTreatmentSymptomsAddictsMethadone